Development of hibernomas in rats dosed with phentolamine mesylate during the 24-month carcinogenicity study.

@article{Poulet2004DevelopmentOH,
  title={Development of hibernomas in rats dosed with phentolamine mesylate during the 24-month carcinogenicity study.},
  author={Frederique M Poulet and Mark R Berardi and William Halliwell and Barbara Hartman and Carol S Auletta and Henry F Bolte},
  journal={Toxicologic pathology},
  year={2004},
  volume={32 5},
  pages={558-66}
}
Phentolamine is a reversible competitive alpha-adrenergic antagonist with similar affinities for alphal and alpha2 receptors. It has a long history of safe clinical use, and was developed as a potential therapy for male erectile dysfunction because of its capacity to increase the arteriolar blood flow to the corpora cavernosa. Phentolamine mesylate was administered to rats by oral gavage at daily doses of 10, 50, and 150 mg/kg for 24 months. A dose-related increase in mortality, ascribed to an… CONTINUE READING